Back to Search Start Over

Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia

Authors :
Han Cheol Lee
Ki Chul Sung
Jinho Shin
Jin Man Cho
Moo Hyun Kim
Sang Hyun Lee
Ki Hoon Han
Xuan Jin
Hyungseop Kim
Hana Lee
Jeong Cheon Ahn
Kihwan Kwon
In Ho Chae
Pum Joon Kim
Jung Hoon Sung
Chang Gyu Park
Min Su Hyon
Jeong Sook Seo
Seung Pyo Hong
Moo Yong Rhee
Jae-Hwan Lee
Kyounghoon Lee
Byung Su Yoo
Woo Shik Kim
Yoonhwa Cho
So-Yeon Choi
Soon Jun Hong
Jin-Yong Hwang
Hyo-Soo Kim
Eun Joo Cho
Ju Han Kim
Source :
Journal of Clinical Hypertension (Greenwich, Conn.)
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg at 8 weeks, and the percent changes from baseline in low‐density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg at 8 weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow‐up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least‐Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg) groups were −19.3 (2.68) mm Hg and −6.69 (2.76) mm Hg. The difference between the two groups was significant (−12.60 (2.77) mm Hg, 95% CI −18.06 to −7.14, P

Details

ISSN :
17517176, 15246175, and 03067688
Volume :
22
Database :
OpenAIRE
Journal :
The Journal of Clinical Hypertension
Accession number :
edsair.doi.dedup.....a9f9dab5c5efdeea3b72febd6d282c04